Immunogenicity Risk Assessment of LNP-Delivered Nucleic Acid Modalities in Therapeutic Applications
Time: 9:25 am
day: Conference Agenda
Details:
- Discussing how these therapies can trigger unwanted innate and adaptive immune responses, potentially impacting treatment efficacy and patient safety
- Describing strategies for product design adaptations during early development stages to minimize immunogenicity
- Outlining recommendations for defining an Immunogenicity Risk Assessment based clinical testing strategy driven by immunogenicity consequences, including streamlined monitoring for minimal impact scenarios and comprehensive testing protocols when safety concerns are anticipated or arise
Speakers:
